VIDEO: Pangenotypic regimen leads to high SVR in all HCV genotypes

[HFIAdmin]

Positive news for patients of any HCV genotypes! After treatment with AbbVie’s new pangenotypic regimen of glecaprevir/pibrentasvir, results have shown an average SVR rate of 97.5% across all HCV genotypes in only 8 weeks of therapy.

bit.ly/2ggJHjr

[jennyjolly]

That's great but what about sides, during/post treatment?

[EDDIEBYOH in reply to jennyjolly]

Will uk still be using peg/interferon for geno type 3 even when there at drugs with less side effects I think so it is all down to money ?

[jennyjolly in reply to EDDIEBYOH]

I was refused Harvoni and offered Viekerak/Riba as cheaper

Decided to leave and self- treat